Loeliger E A, Poller L, Samama M, Thomson J M, Van den Besselaar A M, Vermylen J, Verstraete M
Thromb Haemost. 1985 Aug 30;54(2):515-7.
One of the reasons why oral anticoagulants fell into disrepute is the absence of internationally accepted standardised procedures for controlling the level of anticoagulation. This deplorable situation resulted in over- and under-coagulation and uncertainty in the therapeutic range. International conformity can now be obtained by using an International Normalised Ratio (INR) which is derived from the individual result obtained in a given plasma sample and the International Sensitivity Index (ISI) of the tissue thromboplastin reagent used. Any thromboplastin reagent can be calibrated against an international primary or secondary W. H. O. reference preparation, so as to obtain its International Sensitivity Index. The new system of reporting the level of anticoagulation was designed and can only safely be applied in patients taking oral anticoagulants.
口服抗凝剂声名狼藉的原因之一是缺乏国际公认的控制抗凝水平的标准化程序。这种令人遗憾的情况导致了抗凝过度和不足,以及治疗范围的不确定性。现在,通过使用国际标准化比值(INR)可以实现国际一致性,该比值由给定血浆样本中获得的个体结果和所用组织凝血活酶试剂的国际敏感指数(ISI)得出。任何凝血活酶试剂都可以根据世界卫生组织的国际一级或二级参考制剂进行校准,以获得其国际敏感指数。报告抗凝水平的新系统已经设计出来,并且仅能安全地应用于服用口服抗凝剂的患者。